ROSEN, A LEADING LAW FIRM, Encourages Elanco Animal Health Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELAN

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Elanco Animal Health Incorporated securities during the specified Class Period, indicating potential legal issues for the company related to misleading statements and safety concerns regarding its products [1][5]. Group 1: Class Action Details - The class action lawsuit is filed for securities purchased between November 7, 2023, and June 26, 2024, and interested parties must act by December 6, 2024, to serve as lead plaintiff [1][3]. - Investors who purchased Elanco securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against Elanco - The lawsuit claims that Elanco made false and misleading statements regarding the safety of Zenrelia, a JAK inhibitor for canine dermatology, and its likelihood of meeting approval timelines for Zenrelia and another product, Credelio Quattro [5]. - It is alleged that Elanco's business and financial prospects were overstated, leading to materially false public statements throughout the Class Period [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest ever against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].